secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001326732-23-000024
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor Q2 2023 revenue $45.5M up 51% YoY; net loss narrows to $22M; pipeline advances
--------------------------------------------------------------------------------

- Revenue $45.5M (vs $30.2M Q2 2022), net loss $22.0M ($0.37/diluted) vs $34.0M loss ($0.57) prior.
- Cash, equivalents and marketable securities $531.4M at June 30, 2023, down from $613.5M at Dec 31, 2022.
- Royalty revenue from Alexion's Ultomiris $11.2M; $10M milestone from Zenas for obexelimab Phase 3 start.
- R&D expenses $60.1M, up 28% YoY; guidance projects year-end cash $425-475M, funding through 2025.
- Vudalimab Phase 2 front-line NSCLC expected by year-end; XmAb662 Phase 1 started; XmAb541 IND planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673223000024/0001326732-23-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673223000024/xncr-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001326732-23-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer